相关实验视频
Updated: Jun 6, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.8K
在高风险的肺血栓栓塞与高出血风险的高风险肺血栓塞中,改性输注重组组织等离子体激活剂:一个病例报告
Mohammad Hussein Hasin1, Mostafa Ahmadi1, Vafa Baradaran Rahimi1
1Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hospital practice (1995)
|November 28, 2024
概括
使用重组组织类型等离子体激活剂 (rtPA) 的修改型血栓溶解疗法在4小时内有效治疗高风险肺血栓栓塞 (PTE) 在患有出血风险的患者中. 这种较慢的rtPA输液可能会减少出血并发症.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 紧急医疗 紧急医疗
背景情况:
- 高危肺血栓塞栓症 (PTE) 涉及严重的肺血管阻塞,导致右心室衰竭和血液动力学不稳定.
- 对于高风险的PTE,由于其高死亡率,立即的再注血治疗至关重要.
- 建议进行全身血栓溶解,通常使用复合组织型血原激活剂 (rtPA) 100毫克2小时.
研究的目的:
- 呈现一种高风险PTE病例,该病例已通过修改的rtPA输液方案成功治疗.
- 在高出血风险的患者中评估较慢的rtPA输注速率的疗效和安全性.
主要方法:
- 一名74岁的女性患者患有高风险的PTE和显著的出血风险 (最近的骨盆骨折,头部创伤) 被治疗.
- 一种修改后的100毫克rtPA治疗方案被静脉注射了4个小时.
主要成果:
- 患有高风险PTE和高出血风险的患者通过修改的rtPA输液成功治疗.
- 在4个小时内100毫克rtPA的缓慢输液速度在急性高风险PTE的血栓溶解中表现出有效性.
结论:
- 经过修改的rtPA输液速率为100毫克,持续4小时,是急性高风险PTE的有效血栓缓解疗法.
- 这种较慢的rtPA输注可能会降低出血并发症的风险,使其成为高风险出血患者的可行选择.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
150
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
150
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469

